What is the breast cancer risk associated with hormone replacement therapy (combined estrogen‑progestogen) in post‑menopausal women?

Breast Cancer Risk with Combined Hormone Replacement Therapy

Combined estrogen-progestogen hormone replacement therapy (HRT) modestly increases breast cancer risk, with approximately 8 additional invasive breast cancers per 10,000 women per year of use, though the absolute risk remains small and varies significantly by progestogen type and duration of use. 1

Magnitude of Risk: Understanding the Numbers

The absolute increase in breast cancer risk from combined HRT is modest but real. Based on the highest-quality randomized trial data from the Women's Health Initiative:

• Combined estrogen-progestogen therapy: Hazard ratio (HR) 1.25-1.26, translating to 8 additional breast cancers per 10,000 women per year 1, 2, 3
• This represents an absolute risk increase of only 0.08% annually 4
• The risk increases with duration: 5+ years of use shows HR 1.35, while 15+ years shows HR 1.6 4

Critical distinction: The relative risk (HR of 1.25) sounds alarming, but many experts argue that unless the HR exceeds 3.0, the clinical significance is questionable given the small absolute risk 4. The confidence intervals in the WHI study included 1.0, technically not reaching statistical significance in the primary analysis 4.

Progestogen Type Matters Critically

The type of progestogen used dramatically affects breast cancer risk—this is perhaps the most clinically actionable finding:

• Synthetic progestins (like medroxyprogesterone acetate): OR 1.28-1.31, significantly increased risk 5
• Micronized progesterone: OR 0.99, no significant increase in risk 5
• Specific high-risk combinations: Estradiol/drospirenone (HR 1.51), estradiol/norethisterone (HR 1.66), and estradiol/cyproterone acetate (HR 1.74) 6

This evidence strongly suggests that when progestogen is needed (in women with intact uterus), micronized progesterone appears safer than synthetic progestins 5.

Estrogen-Only Therapy: A Different Story

For women who have had hysterectomy and can use estrogen alone:

• Estrogen-only therapy actually reduced breast cancer incidence: HR 0.77, with 8 fewer breast cancers per 10,000 women per year 2, 3
• Breast cancer mortality was also reduced: HR 0.37 2
• This protective effect persisted through nearly 11 years of follow-up 2

This finding is robust from the WHI randomized trial and represents high-quality evidence 2, 3, 7.

Duration and Timing Considerations

Risk increases with duration of use:

• Short-term use (<5 years): Minimal to no significantly increased risk for most formulations 4
• 5-9 years of use: HR 1.46 8
• 10+ years of use: HR 1.46-1.6, with absolute excess risk still only ~0.75% 4

Timing of initiation matters: Starting combined HRT within 3 years of menopause onset carries higher risk even with short duration (<2 years) compared to delayed initiation, except for estrogen-progesterone combinations 9.

Important caveat: Risk disappears 1-5 years after discontinuation 4, suggesting HRT may promote pre-existing disease rather than initiate new cancers 4.

Clinical Decision Framework

For women considering HRT, the decision algorithm should include:

1. Hysterectomy status:

   • Prior hysterectomy → Estrogen-only therapy is preferred (actually reduces breast cancer risk)
   • Intact uterus → Combined therapy needed for endometrial protection

2. If combined therapy needed, progestogen selection:

   • First choice: Micronized progesterone (no increased breast cancer risk) 5
   • Avoid if possible: Synthetic progestins, especially drospirenone, norethisterone, and cyproterone acetate 5, 6

3. Duration planning:

   • Use lowest effective dose for shortest duration needed 1
   • Risk-benefit ratio shifts unfavorably after 5 years for combined therapy 4, 8
   • Consider stopping after symptom resolution and reassessing need

4. Individual risk factors:

   • Family history of breast cancer does NOT appear to further increase risk from HRT 4
   • Age matters: older women (60-64) have higher relative risk (1.71) 8

Balancing Benefits Against Risks

The USPSTF guideline provides useful context: per 10,000 women taking combined HRT for 1 year, there are 8 additional breast cancers BUT also 6 fewer colorectal cancers and 5 fewer hip fractures 1. The net harm-benefit calculation depends heavily on individual baseline risks and symptom severity.

For symptom management (not chronic disease prevention), HRT remains appropriate with informed consent, particularly when using safer formulations like estrogen-only (post-hysterectomy) or estrogen with micronized progesterone 1, 5.

Common Pitfalls to Avoid

• Don't extrapolate combined therapy data to estrogen-only therapy—they have opposite effects on breast cancer risk 2, 3, 7
• Don't assume all progestogens carry equal risk—micronized progesterone appears substantially safer 5
• Don't confuse relative risk with absolute risk—the HR of 1.25 translates to only 8 additional cases per 10,000 women-years 1
• Don't overlook that risk disappears after stopping—suggesting promotion rather than initiation of cancer 4